HC Wainwright Reiterates Hold Rating for Trillium Therapeutics (NASDAQ:TRIL)

Share on StockTwits

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR)‘s stock had its “hold” rating reiterated by equities researchers at HC Wainwright in a report released on Monday, Stock Target Advisor reports.

A number of other brokerages have also commented on TRIL. Cowen reissued a “buy” rating on shares of Trillium Therapeutics in a report on Thursday, August 15th. Zacks Investment Research lowered Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th.

Shares of NASDAQ TRIL opened at $0.28 on Monday. The firm has a market cap of $7.80 million, a price-to-earnings ratio of -0.12 and a beta of 2.18. The business’s 50-day simple moving average is $0.28 and its 200-day simple moving average is $0.36. Trillium Therapeutics has a 52 week low of $0.24 and a 52 week high of $3.20.

An institutional investor recently bought a new position in Trillium Therapeutics stock. Marshall Wace LLP acquired a new stake in shares of Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 110,282 shares of the biotechnology company’s stock, valued at approximately $73,000. Marshall Wace LLP owned about 0.42% of Trillium Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 23.90% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.